News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
289,204 Results
Type
Article (14838)
Company Profile (34)
Press Release (274332)
Section
Business (80509)
Career Advice (1330)
Deals (15972)
Drug Delivery (34)
Drug Development (48417)
Employer Resources (54)
FDA (7725)
Job Trends (6476)
News (151167)
Policy (12599)
Tag
Academia (997)
Alliances (15161)
Alzheimer's disease (672)
Antibody-drug conjugate (ADC) (71)
Approvals (7758)
Artificial intelligence (114)
Bankruptcy (114)
Best Places to Work (5669)
Breast cancer (193)
Cancer (1319)
Cardiovascular disease (88)
Career advice (1031)
Cell therapy (207)
Clinical research (41566)
Collaboration (412)
Compensation (248)
COVID-19 (1211)
Data (1312)
Diabetes (142)
Diagnostics (2667)
Earnings (49802)
Events (46453)
Executive appointments (317)
FDA (8362)
Funding (365)
Gene therapy (148)
GLP-1 (402)
Government (1635)
Healthcare (8140)
Infectious disease (1279)
Interviews (248)
IPO (9632)
Job creations (1183)
Job search strategy (910)
Layoffs (183)
Legal (2028)
Lung cancer (194)
Lymphoma (106)
Manufacturing (114)
Medical device (5822)
Medtech (5822)
Mergers & acquisitions (6656)
Metabolic disorders (361)
Neuroscience (940)
NextGen: Class of 2025 (2416)
Non-profit (2087)
Northern California (1483)
Obesity (179)
Opinion (89)
Parkinson's disease (73)
Patents (85)
People (13197)
Phase I (10323)
Phase II (17082)
Phase III (17696)
Pipeline (662)
Postmarket research (1374)
Preclinical (3430)
Radiopharmaceuticals (122)
Rare diseases (196)
Real estate (1529)
Regulatory (9899)
Research institute (918)
Resumes & cover letters (256)
Southern California (1232)
Startups (1076)
United States (11653)
Vaccines (333)
Weight loss (107)
Date
Today (85)
Last 7 days (550)
Last 30 days (1914)
Last 365 days (21170)
2025 (3683)
2024 (20538)
2023 (21229)
2022 (25568)
2021 (26883)
2020 (25280)
2019 (20186)
2018 (15167)
2017 (15632)
2016 (13557)
2015 (16116)
2014 (11829)
2013 (8845)
2012 (9257)
2011 (9743)
2010 (8375)
Location
Africa (375)
Asia (20449)
Australia (3829)
California (3272)
Canada (977)
China (267)
Colorado (144)
Connecticut (166)
Delaware (96)
Europe (42035)
Florida (421)
Georgia (103)
Illinois (256)
Indiana (158)
Japan (108)
Maryland (368)
Massachusetts (2334)
Michigan (72)
Minnesota (196)
New Jersey (952)
New York (886)
North Carolina (476)
Northern California (1483)
Ohio (91)
Pennsylvania (648)
South America (542)
Southern California (1232)
Texas (465)
Utah (80)
Virginia (72)
Washington State (312)
289,204 Results for "3".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 million Management to host conference call at 8:00 AM Eastern time on Thursday, February 6, 2024
February 6, 2025
·
24 min read
Mergers & acquisitions
Bain Bets Big on Japanese Market With $3.3B Tanabe Buy
The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences market, recently revitalized by more industry-friendly policy changes from the government.
February 10, 2025
·
1 min read
·
Tristan Manalac
Deals
Lilly Drops Up to $2.5B for Scorpion’s PI3K-inhibitor Molecule
The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.
January 13, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
March 3, 2025
·
12 min read
3 Major Product Releases at 3Shape Discover Event
3Shape announces the launch of three exciting solutions at its 3Shape Discover digital dentistry event.
June 7, 2024
·
3 min read
Approvals
Roche Wins First-Line Breast Cancer Nod for Oral PI3K Blocker, Projects $2.3B in Peak Sales
With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K inhibitor Piqray, which last year generated $505 million in revenue.
October 11, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Complement 3 Glomerulopathy Market Size to Reach USD 12.3 Billion by 2035, Impelled by Advancements in Targeted Drug Therapies
January 29, 2025
·
12 min read
Press Releases
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
February 10, 2025
·
7 min read
Press Releases
XARlabs Closes $2.3 Million in Seed Funding
February 10, 2025
·
3 min read
Press Releases
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
March 3, 2025
·
14 min read
1 of 28,921
Next
